IFPMA at DIA Europe 2024

12 - 14 March 2024 Brussels, BE

12 - 14 March 2024


DIA Europe


Brussels, BE


This event has now passed. To browse our upcoming events click here.

IFPMA will be at DIA Europe 2024. The conference is designed to drive insights into action by connecting key policy discussions to real-world knowledge and accelerate growth and performance in the drug development ecosystem.

This year, the conference will focus on sustainability, innovation, and collaboration – three key pillars for shaping the future of healthcare. From the environmental impact of pharmaceuticals and the drug development lifecycle to sustainable partnerships and healthcare systems, DIA Europe 2024 is an opportunity to discuss how collaboration and innovation can support sustainability in healthcare and each stakeholder’s role in making it happen.

IFPMA will lead a session on the operationalization of the African Medicines Agency.

IFPMA members will also participate in several sessions during DIA Europe 2024.

Registration details

Program and registrations



12 March, 13:50-15:00 CET Operationalization of AMA: Building an equitable, sustainable regulatory ecosystem across Africa

As efforts on the African continent are concentrated on accelerating the operationalization of the African Medicines Agency (AMA), it is important to consider and leverage the experience and learnings from mature regulatory agencies such as EMA and international work-sharing schemes like WHO CRP, EUM4All, Swissmedic MAGHP, and ACCESS Consortium.

As a new, modern regulatory agency, AMA has the potential to establish a robust and unique regulatory framework to address gaps and inconsistencies in national regulatory systems as well as optimize technical capabilities, regulatory expertise, and digital tools to drive efficient and sustainable regulatory operations at the continental level.

Great strides have been made in enhancing regulatory harmonization and convergence in Africa via the Africa Medicines Regulatory Harmonization initiative and its partnership platform, and the Regional Economic Communities’ (RECs) implementation of several joint assessment procedures (JAPs) (e.g., EAC, ZAZIBONA, and ECOWAS).

The need to strengthen harmonization of other parts of the registration is also imperative. To further enhance collaboration and work-sharing, AMA must consider lessons learned from the various regional JAPs and international regulatory work-sharing procedures. Given the positive impact of digitalization, digital tools can also drive efficiencies in the AMA’s operations, benefitting all stakeholders in the regulatory ecosystem, especially patients.

This session will highlight regional and international experiences from JAPs, and how these can uplift the Africa regulatory ecosystem, including by advancing maturity of several national regulatory agencies and RECs in Africa. The session will also cover the adoption of digitization initiatives on the continent and offer a platform for engagement and dialogue on optimizing operationalization of the AMA.

More information about the session here.


12 March, 13:50-15:00 CET Collaborative review and reliance – grasping the opportunity

This session will focus on the current status of reliance and recognition between European and other global regulators. The speakers will cover flagship topics of high interest to industry, including ICMRA pilot programs, the experience of industry innovators in developing a global vaccines reliance pilot, and reflections on the status of reliance and recognition in GMP.

Regulators and industry will offer reflections and proposals for how the future state can increasingly use reliance and recognition to enable more harmonized and streamlined approaches to assessment of the CMC dossier and assurance of GMP, with the ultimate goal of enabling more accelerated and secure supply of medicines to patients.

Stephan Roenninger, Amgen, will present on behalf of IFPMA on the future of inspection frameworks.

More information about the session here.

13 March, 13:10-14:40 CET Global innovation in manufacturing and CMC

This session will focus on the global regulatory frameworks for enabling innovation in manufacturing and quality. Innovation includes the development and manufacture of new types of products, new manufacturing platforms, innovative technologies such as model-based controls, the wider scope of and new analytical technologies.

The implementation of new digital tools and manufacturing technologies are key to the evolution of manufacturing, which can be enabled by tools such platform technology master files. The session will reflect on how groups such as the new EMA Quality Innovation Group is seeking to lead the transformation of medicines’ manufacturing in Europe and how this is linked to fast moving initiatives outside of Europe, such as FDA FRAME and platform design technology programs, ICH, and ICMRA collaborative initiatives under the PQKMS umbrella, including collaborative assessments. The discussion will also focus on how collaboration and the identification of risk can already enable technology.

Gert Thurau, Roche, will bring a perspective on the use of artificial intelligence in manufacturing on behalf of IFPMA.

More information about the session here.